INMB

Announcements

Nothing here yet

Daily updates

Nothing here yet

FDA designations

Nothing here yet

News

• INmune Bio advanced Ebstrocel toward European marketing authorization through regulatory submissions to the EMAAug 26, 2026
• INmune Bio reported preclinical data showing XPro1595 prevented Alzheimer's-related pathology after brain injuryJul 15, 2026
• INmune Bio received FDA Fast Track designation for XPro1595 in early Alzheimer's diseaseMay 14, 2026
• INmune Bio reached FDA alignment on an integrated Phase 2b/3 registration pathway for XPro1595 in early Alzheimer’s diseaseFeb 12, 2026
• INmune Bio announces submission of Phase 2 MINDFuL trial results in Alzheimer's disease to npj Dementia, a Nature Portfolio journalSep 29, 2025